Additionally, monitoring biomarkers could guide treatment duration and dose adjustments, moving beyond one-size-fits-all protocols toward personalized therapeutic approaches optimized for individual patient characteristics and treatment goals
Comparison of the kinetic parameters revealed that ScGrx7 has two distinct glutathione interaction sites
10.1002/jms.3233 37 PoglianoJ.PoglianoN.SilvermanJ
Affected individuals may drink 320 liters per day
At ACR Convergence 2025, researchers from Toronto and NYU reported that PsA patients starting GLP-1 receptor agonists had significant improvements in joint counts, CRP, pain scores, and DAPSA disease activity scores within one year of treatment. Whats interesting is that you dont seem to need a large dose to see these benefits
CMS has unveiled its BALANCE model, a voluntary Medicare and Medicaid coverage pathway for GLP-1s that includes price negotiations and supplemental lifestyle support, with coverage beginning in 2026 for Medicaid and 2027 for Medicare Part D [2]